BACKGROUND: Scabies is a neglected tropical disease of the skin, causing severe itching, stigmatizing skin lesions and systemic complications. Since 2015, the DerMalawi project provide an integrated skin diseases clinics and Tele-dermatology care in Malawi. Clinic based data suggested a progressive increase in scabies cases observed. To better identify and treat individuals with scabies in the region, we shifted from a clinic-based model to a community based outreach programme. METHODOLOGY/PRINCIPAL FINDINGS: From May 2015, DerMalawi project provide integrated skin diseases and Tele-dermatological care in the Nkhotakota and Salima health districts in Malawi. Demographic and clinical data of all patients personally attended are recorded. Due to a progressive increase in the number of cases of scabies the project shifted to a community-based outreach programme. For the community outreach activities, we conducted three visits between 2018 to 2019 and undertook screening in schools and villages of Alinafe Hospital catchment area. Treatment was offered for all the cases and school or household contacts. Scabies increased from 2.9% to 39.2% of all cases seen by the DerMalawi project at clinics between 2015 to 2018. During the community-based activities approximately 50% of the population was assessed in each of three visits. The prevalence of scabies was similar in the first two rounds, 15.4% (2392) at the first visit and 17.2% at the second visit. The prevalence of scabies appeared to be lower (2.4%) at the third visit. The prevalence of impetigo appeared unchanged and was 6.7% at the first visit and 5.2% at the final visit. CONCLUSIONS/SIGNIFICANCE: Prevalence of scabies in our setting was very high suggesting that scabies is a major public health problem in parts of Malawi. Further work is required to more accurately assess the burden of disease and develop appropriate public health strategies for its control.
Community Health Services , Scabies/diagnosis , Scabies/epidemiology , Acaricides/therapeutic use , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Malawi/epidemiology , Male , Rural Population , Scabies/drug therapy , Young Adult
Exophiala/isolation & purification , Opportunistic Infections/microbiology , Phaeohyphomycosis/microbiology , Adenocarcinoma/complications , Adenocarcinoma/secondary , Aged , Antifungal Agents/therapeutic use , Bone Neoplasms/complications , Bone Neoplasms/secondary , Brain Neoplasms/complications , Brain Neoplasms/secondary , Elbow , Fatal Outcome , Humans , Immunocompromised Host , Itraconazole/therapeutic use , Male , Opportunistic Infections/drug therapy , Opportunistic Infections/etiology , Phaeohyphomycosis/drug therapy , Phaeohyphomycosis/etiology , Sigmoid Neoplasms/complications
No disponible
Humans , Male , Aged , Phthirus/pathogenicity , Lice Infestations/diagnosis , Phthirus/microbiology , Phthirus/ultrastructure , Pediculus , Lice Infestations/drug therapy
La queratosis actínica (QA) es motivo de consulta frecuente tanto en atención primaria como en atención especializada. Supone el tercer o cuarto motivo más frecuente de consulta en dermatología, llegando a representar hasta un 5-6% de los pacientes atendidos. Además, se ha observado que esta prevalencia ha ido en aumento en los últimos 10 años, en comparación con otras dermatosis, y se prevé que seguirá aumentado por la mayor esperanza de vida y por los cambios de hábitos de exposición solar acontecidos desde mediados del siglo pasado. El objetivo de este artículo es actualizar los conceptos de QA y de campo de cancerización, y exponer las herramientas terapéuticas disponibles actualmente (AU)
Actinic keratosis (AK) is a common reason for consultation in both Primary Care and Specialised Care. It is the third or fourth most common reason for consultation in dermatology, accounting for up to 5-6% of patients attended. It has also been observed that its prevalence has been increasing in the last 10 years, compared to other dermatoses. This is also expected to continue to increase due to longer life expectancy, and by the changes in sun exposure habits since the middle of the last century. The aim of this article is to update the concepts of AK, cancerisation field and to present the currently available therapeutic tools (AU)
Humans , Keratosis, Actinic/epidemiology , Precancerous Conditions/epidemiology , Solar Radiation/adverse effects , Carcinoma, Squamous Cell/epidemiology , Diagnosis, Differential , Cryotherapy , Electrosurgery , Fluorouracil/therapeutic use , Diclofenac/therapeutic use , Phototherapy
Actinic keratosis (AK) is a common reason for consultation in both Primary Care and Specialised Care. It is the third or fourth most common reason for consultation in dermatology, accounting for up to 5-6% of patients attended. It has also been observed that its prevalence has been increasing in the last 10years, compared to other dermatoses. This is also expected to continue to increase due to longer life expectancy, and by the changes in sun exposure habits since the middle of the last century. The aim of this article is to update the concepts of AK, cancerisation field and to present the currently available therapeutic tools.
Keratosis, Actinic/therapy , Humans , Keratosis, Actinic/diagnosis
Carcinoma, Squamous Cell/secondary , Lung Neoplasms/pathology , Skin Neoplasms/secondary , Aged , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/pathology , Fatal Outcome , Humans , Lung Neoplasms/diagnostic imaging , Male , Radiography , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Thorax
